Showing the single result
-
4%
DOUBLE MARKER – FIRST TRIMESTER(DOUBLE MARKER FIRST TRIMESTER 8-13 WEEK (FMF CERTIFIED)0
The first-trimester double marker test is a non-invasive prenatal blood test that checks for elevated levels of Free Beta-hCG and PAPP-A, two hormones or proteins that can indicate a higher risk of chromosomal abnormalities like Down syndrome, Edward syndrome, and Patau syndrome in the developing baby. The test provides a risk assessment, not a diagnosis, and is performed between weeks 9 and 13 of pregnancy, ideally combined with a nuchal translucency (NT) ultrasound for increased accuracy. High-risk results are typically followed up with more definitive diagnostic tests such as Non-Invasive Prenatal Testing (NIPT) or amniocentesis.
Purpose- To assess the risk of chromosomal abnormalities, specifically Down syndrome (Trisomy 21), Edward syndrome (Trisomy 18), and Patau syndrome (Trisomy 13).
- To provide early information for making informed decisions about the pregnancy.
Key Components- Free Beta-hCG: A hormone whose levels are often higher in pregnancies with Down syndrome.
- PAPP-A (Pregnancy-Associated Plasma Protein-A): A protein supporting fetal and placental development; lower levels can be associated with chromosomal abnormalities.
- Maternal Age & Gestational Age: These factors are included in the risk calculation.
Procedure- Blood Draw: A blood sample is taken from the pregnant woman.
- Nuchal Translucency (NT) Scan: An ultrasound is performed to measure the fluid-filled space at the back of the baby’s neck; a larger NT measurement can indicate a higher risk.
- Combined Risk Calculation: The blood test results are combined with the NT scan findings and maternal age to calculate the overall risk.
Interpretation & Next Steps-
Screening Test:
The double marker test is a screening tool, not a diagnostic one; it provides a risk assessment, not a definitive diagnosis.
-
Low-Risk Result:
Indicates a low likelihood of the baby having the screened chromosomal abnormalities.
-
High-Risk Result:
Suggests a higher probability of chromosomal abnormality and warrants further diagnostic testing.
-
Follow-Up Tests:Confirmatory diagnostic tests like NIPT, amniocentesis, or chorionic villus sampling (CVS) may be recommended.
₹2,607.00Original price was: ₹2,607.00.₹2,500.00Current price is: ₹2,500.00. - To assess the risk of chromosomal abnormalities, specifically Down syndrome (Trisomy 21), Edward syndrome (Trisomy 18), and Patau syndrome (Trisomy 13).